Abbott

Abbott, Janssen, Pharmacyclics to develop companion test for leukemia therapy

Friday, February 22, 2013 11:16 AM

Global healthcare company Abbott has formed a collaboration with Janssen Biotech and Pharmacyclics, a biopharmaceutical company based in Sunnyvale, Calif., to explore the benefits of Abbott's proprietary FISH (fluorescence in situ hybridization) technology for use in developing a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.

More... »


Abbott completes separation of research-based pharmaceuticals business

Wednesday, January 2, 2013 02:09 PM

Global healthcare company Abbott Laboratories has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie began trading independently on the New York Stock Exchange on Jan. 2, 2013, under the symbol "ABBV."

More... »


Abbott board approves separation of AbbVie

Thursday, November 29, 2012 01:46 PM

The board of directors of Illinois-based Abbott has approved the separation of its research-based pharmaceuticals business, to be known as AbbVie, and declared a special dividend distribution of all outstanding shares of AbbVie common stock.

More... »

Abbott announces phase III Hep C program details

Friday, November 16, 2012 02:25 PM

Abbott Laboratories, a global healthcare company, has released details on its phase III hepatitis C registration program following promising results from its phase IIb clinical trial, known as Aviator.

More... »

Insmed appoints Andrew Drechsler as CFO

Thursday, November 8, 2012 02:49 PM

Insmed, a biopharmaceutical company focused on inhaled therapeutics for serious lung diseases, has appointed Andrew Drechsler to the position of chief financial officer.

More... »

Seattle Genetics, Abbott expand antibody-drug conjugate collaboration

Wednesday, October 24, 2012 11:02 AM

Seattle Genetics, a Bothell, Wash.-based biotech focused on monoclonal antibody-based therapies for the treatment of cancer, has expanded its antibody-drug conjugate (ADC) collaboration with Abbott Laboratories, a global healthcare company.

More... »

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

Abbott, Astellas collaborate on CMV vaccine trial

Monday, September 10, 2012 11:03 AM

Abbott has signed an agreement to collaborate with Astellas Pharma Global Development in a phase III clinical trial for ASP0113 (TransVax), an investigational vaccine licensed from Vical for preventing cytomegalovirus (CMV) reactivation in transplant patients.

More... »

Abbott, ChemDiv Research ink Russian R&D collaborations

Tuesday, July 10, 2012 03:30 PM

Abbott Laboratories, a global healthcare company, and ChemDiv Research Institute (CDRI), the research entity of ChemRar Hi-Tech Centre, have signed an agreement to launch several R&D projects in Russia.

More... »

Seven global biopharmas form neuroscience consortium

Wednesday, June 20, 2012 02:56 PM

Seven global biopharmaceutical companies have formed the Massachusetts Neuroscience Consortium, which will fund pre-clinical neuroscience at Massachusetts academic and research institutions. Participants include Abbott, Biogen Idec, EMD Serono, Janssen Research & Development, Merck, Pfizer and Sunovion Pharmaceuticals.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs